Article
CHENG Lili, GAO Jie, WANG Tao
Objective To compare the efficacy of faricimab and ranibizumab in the treatment of severe non-proliferative
diabetic retinopathy(NPDR) with diabetic macular edema(DME), and their effects on inflammatory cytokines and visual
acuity. Methods Eighty patients with severe NPDR complicated with DME from Linyi People's Hospital were selected
and randomly divided into the observation group and the control group by simple random sorting method, with 40 cases
in each group. The observation group was treated with faricimab, while the control group was treated with ranibizumab.
The efficacy, central retinal thickness(CRT), best corrected visual acuity(BCVA), intraocular pressure, inflammatory
factors[high-sensitivity C reactive protein(hs-CRP), interleukin(IL)-6, IL-8, tumor necrosis factor(TNF)-α], serum indicators[angiopoietin(Ang)-2, vascular endothelial growth factor(VEGF), intercellular adhesion molecule(ICAM)-1,
connective tissue growth factor(CTGF)] and the occurrence of adverse events were compared between the two groups.
Results After treatment, the efficacy of the observation group was better than that of the control group(P＜0.05). After
treatment, both groups had an increase in BCVA compared with before treatment(P＜0.05). CRT, intraocular pressure, hs-
CRP, IL-6, TNF-α, IL-8, Ang-2, VEGF, ICAM-1, CTGF were all decreased compared with before treatment(P＜0.05),
and the change in the observation group was greater than that in the control group(P＜0.05). There was no significant
difference in the occurrence of complications between the two groups(P＞0.05). Conclusion Faricimab is more effective
than ranibizumab in the treatment of patients with severe NPDR combined with DME, which can effectively improve
visual acuity, reduce inflammation, and improve the levels of VEGF, CTGF, etc., with a favorable safety profile.
